Commercial
Advanced Search
  
  
  
  
  
  
  
  
  
  
MPattachmentdataPub
adae91f7-712f-480d-ab7c-efe812f94865.aspx
  
08.01.40gLanreotide(Somatuline®Depot)08.01.40gPharmacy (08)Lanreotide (Somatuline® Depot)adae91f7-712f-480d-ab7c-efe812f948656725Lanreotide (Somatuline® Depot)08.01.40
{"6726": {"Id":6726,"MPAttachmentLetter":"A","Title":"ICD-10 CODES AND NARRATIVES","MPPolicyAttachmentInternalSourceId":9068,"PolicyAttachmentPageName":"76f498a6-1110-4318-ab79-6a224bc36273"},}
42302818-e908-4f2f-88f6-0e0831441240.aspx
  
11.06.10aLaparoscopic,Percutaneous,andTranscervicalTechniquesforUterineFibroidMyolysis11.06.10aSurgery (11)Laparoscopic, Percutaneous, and Transcervical Techniques for Uterine Fibroid Myolysis42302818-e908-4f2f-88f6-0e08314412406412Laparoscopic, Percutaneous, and Transcervical Techniques for Uterine Fibroid Myolysis11.06.10
0afa0ba8-5ee1-405f-9af3-fc53c5e18754.aspx
  
08.01.33jLeuprolideAcetate(Camcevi™,Eligard®,Fensolvi®,LupronDepot®)08.01.33jPharmacy (08)Leuprolide Acetate (Camcevi™, Eligard®, Fensolvi®, Lupron Depot®)0afa0ba8-5ee1-405f-9af3-fc53c5e187546956Leuprolide Acetate (Camcevi™, Eligard®, Fensolvi®, Lupron Depot®)08.01.33
{"6957": {"Id":6957,"MPAttachmentLetter":"A","Title":"LEUPROLIDE ACETATE (LUPRON DEPOT - J1950)","MPPolicyAttachmentInternalSourceId":9223,"PolicyAttachmentPageName":"9c44b8f7-2ef6-4349-a051-bc3883f40b59"},"6958": {"Id":6958,"MPAttachmentLetter":"D","Title":"LEUPROLIDE ACETATE (ELIGARD and LUPRON DEPOT- J9217)","MPPolicyAttachmentInternalSourceId":9224,"PolicyAttachmentPageName":"21b9a42e-d213-409c-9bb3-3e24ce833842"},"6959": {"Id":6959,"MPAttachmentLetter":"B","Title":"LEUPROLIDE ACETATE (FENSOLVI- J1951)","MPPolicyAttachmentInternalSourceId":9225,"PolicyAttachmentPageName":"a48dfec0-403f-47a7-a001-15eee3ef1896"},"6960": {"Id":6960,"MPAttachmentLetter":"C","Title":"LEUPROLIDE MESYLATE (CAMCEVI- J1952)","MPPolicyAttachmentInternalSourceId":9226,"PolicyAttachmentPageName":"926d8c23-ae85-4ae6-a5f3-3e9cb0b075b9"},}
20e97736-e90b-476b-b446-7069809a5e16.aspx
  
08.02.22Lifileucel(Amtagvi™)08.02.22Pharmacy (08)Lifileucel (Amtagvi™)20e97736-e90b-476b-b446-7069809a5e166815Lifileucel (Amtagvi™)08.02.22
e44b660b-8f00-4a25-9ba1-4e4d7cca9593.aspx
  
11.08.03mLipectomyandLiposuction11.08.03mSurgery (11)Lipectomy and Liposuctione44b660b-8f00-4a25-9ba1-4e4d7cca95936528Lipectomy and Liposuction11.08.03
6519dbf4-5c4c-4b8b-afac-bdb1355a3748.aspx
  
08.00.59cLoncastuximabtesirine-lpyl(Zynlonta®)08.00.59cPharmacy (08)Loncastuximab tesirine-lpyl (Zynlonta®)6519dbf4-5c4c-4b8b-afac-bdb1355a37486741Loncastuximab tesirine-lpyl (Zynlonta®)08.00.59
9cb0b199-78ba-4c3b-b1c6-872a97a7e3de.aspx
  
08.02.15Lovotibeglogeneautotemcel(Lyfgenia®)08.02.15Pharmacy (08)Lovotibeglogene autotemcel (Lyfgenia®)9cb0b199-78ba-4c3b-b1c6-872a97a7e3de6908Lovotibeglogene autotemcel (Lyfgenia®)08.02.15
df482a29-ee3c-4fca-a17e-2b2ceeb89658.aspx
  
05.00.59pLowerLimbProstheses05.00.59pDME (05)Lower Limb Prosthesesdf482a29-ee3c-4fca-a17e-2b2ceeb896586844Lower Limb Prostheses05.00.59
{"6845": {"Id":6845,"MPAttachmentLetter":"A","Title":"HCPCS Level II Code Number(s) and Narrative(s)","MPPolicyAttachmentInternalSourceId":8973,"PolicyAttachmentPageName":"62262151-c7b9-48ac-89ac-ab1ab9cc3151"},}
4e39b453-4a5b-4a91-885a-e7b7ab9d5eb9.aspx
  
09.00.31dLowOsmolarContrastAgents09.00.31dRadiology (09)Low Osmolar Contrast Agents4e39b453-4a5b-4a91-885a-e7b7ab9d5eb95061Low Osmolar Contrast Agents09.00.31
295d8e7d-3ecd-4b08-a01f-1dd5d03a7ba3.aspx
  
08.01.74aLumasiran(Oxlumo®)​08.01.74aPharmacy (08)Lumasiran (Oxlumo®)​295d8e7d-3ecd-4b08-a01f-1dd5d03a7ba36902Lumasiran (Oxlumo®)​08.01.74
f102071f-bcc3-4f35-b7c0-67c5e93a4e42.aspx
  
08.01.67cLurbinectedin(Zepzelca®)08.01.67cPharmacy (08)Lurbinectedin (Zepzelca®)f102071f-bcc3-4f35-b7c0-67c5e93a4e426833Lurbinectedin (Zepzelca®)08.01.67
7c2f0a75-ff83-4755-8343-648fb98cb970.aspx
  
08.00.10dLuspatercept–aamt(Reblozyl®)08.00.10dPharmacy (08)Luspatercept–aamt (Reblozyl®)7c2f0a75-ff83-4755-8343-648fb98cb9706911Luspatercept–aamt (Reblozyl®)08.00.10
1badf96b-891e-4a73-85aa-80b5741a373d.aspx
  
08.01.57aLutathera®(LutetiumLu177Dotatate)(IndependenceAdministrators)08.01.57aPharmacy (08)Lutathera® (Lutetium Lu 177 Dotatate) (Independence Administrators)1badf96b-891e-4a73-85aa-80b5741a373d7067Lutathera® (Lutetium Lu 177 Dotatate) (Independence Administrators)08.01.57
166425f2-1f29-4928-94c9-a173194c0858.aspx
  
06.02.01kLymeDisease:DiagnosisandIntravenous(IV)AntibioticTherapy06.02.01kPathology and Laboratory (06)Lyme Disease: Diagnosis and Intravenous (IV) Antibiotic Therapy166425f2-1f29-4928-94c9-a173194c08586855Lyme Disease: Diagnosis and Intravenous (IV) Antibiotic Therapy06.02.01
947402ea-526f-46ed-a776-8a88e3c62b38.aspx
  
09.00.45lMagneticResonanceImaging(MRI)ContrastAgents09.00.45lRadiology (09)Magnetic Resonance Imaging (MRI) Contrast Agents947402ea-526f-46ed-a776-8a88e3c62b386759Magnetic Resonance Imaging (MRI) Contrast Agents09.00.45
21d96d18-d927-4380-8f98-20b4e8386da5.aspx
  
11.06.06hMagneticResonanceImaging(MRI)-GuidedFocusedUltrasoundAblation11.06.06hSurgery (11)Magnetic Resonance Imaging (MRI)-Guided Focused Ultrasound Ablation21d96d18-d927-4380-8f98-20b4e8386da56983Magnetic Resonance Imaging (MRI)-Guided Focused Ultrasound Ablation11.06.06
9583e091-b0b2-4403-8739-e8c1e7711519.aspx
  
08.01.37eMaintenanceTreatmentofOpioidorAlcoholUseDisorder08.01.37ePharmacy (08)Maintenance Treatment of Opioid or Alcohol Use Disorder 9583e091-b0b2-4403-8739-e8c1e77115196975Maintenance Treatment of Opioid or Alcohol Use Disorder 08.01.37
{"6976": {"Id":6976,"MPAttachmentLetter":"A","Title":"ICD10 Codes","MPPolicyAttachmentInternalSourceId":9349,"PolicyAttachmentPageName":"87975917-77b1-4c62-a4fe-476cf1c66370"},}
8976551b-e116-46a1-9813-0c82b43e743d.aspx
  
11.14.24bManipulationUnderAnesthesia11.14.24bSurgery (11)Manipulation Under Anesthesia8976551b-e116-46a1-9813-0c82b43e743d6114Manipulation Under Anesthesia11.14.24
772e2554-8368-4fbb-b043-a80f729505ce.aspx
  
05.00.12jManualWheelchairs05.00.12jDME (05)Manual Wheelchairs772e2554-8368-4fbb-b043-a80f729505ce6207Manual Wheelchairs05.00.12
{"6208": {"Id":6208,"MPAttachmentLetter":"A","Title":"HCPCS Codes for Manual Wheelchairs","MPPolicyAttachmentInternalSourceId":8579,"PolicyAttachmentPageName":"b18c2cc3-99d2-44fe-a6c5-4d44e69a37b0"},}
9227af42-a430-48f7-9904-8ca65fcec746.aspx
  
08.01.75dMargetuximab-cmkb(Margenza)08.01.75dPharmacy (08)Margetuximab-cmkb (Margenza)9227af42-a430-48f7-9904-8ca65fcec7466864Margetuximab-cmkb (Margenza)08.01.75
{"6865": {"Id":6865,"MPAttachmentLetter":"A","Title":"ICD 10 Codes","MPPolicyAttachmentInternalSourceId":9095,"PolicyAttachmentPageName":"8f3508ce-ed64-4d3e-a0dd-68d24aba3702"},}
e2f8796c-a9d5-4675-8532-35b82f7ebbd4.aspx
  
00.01.48dMarijuanaforMedicalUse00.01.48dAdministrative (00)Marijuana for Medical Usee2f8796c-a9d5-4675-8532-35b82f7ebbd45488Marijuana for Medical Use00.01.48
89422972-29b8-4ad7-a651-3fa27674e81e.aspx
  
07.11.02fMeasurementofExhaledNitricOxideandBreathCondensateintheDiagnosisandManagementofAsthmaandOtherRespiratoryDisorders07.11.02fMedicine (07)Measurement of Exhaled Nitric Oxide and Breath Condensate in the Diagnosis and Management of Asthma and Other Respiratory Disorders89422972-29b8-4ad7-a651-3fa27674e81e7050Measurement of Exhaled Nitric Oxide and Breath Condensate in the Diagnosis and Management of Asthma and Other Respiratory Disorders07.11.02
65bbc3e9-8e40-432f-82c2-3f804df0b4c1.aspx
  
06.02.39dMeasurementofSerumAntibodiestoandMeasurementofSerumLevelsofBiologics06.02.39dPathology and Laboratory (06)Measurement of Serum Antibodies to and Measurement of Serum Levels of Biologics65bbc3e9-8e40-432f-82c2-3f804df0b4c16349Measurement of Serum Antibodies to and Measurement of Serum Levels of Biologics06.02.39
9439e929-7846-47e0-909c-412ceae03cb5.aspx
  
05.00.70dMechanicalStretchingDevicesfortheTreatmentofJointStiffnessorContractures05.00.70dDME (05)Mechanical Stretching Devices for the Treatment of Joint Stiffness or Contractures9439e929-7846-47e0-909c-412ceae03cb57055Mechanical Stretching Devices for the Treatment of Joint Stiffness or Contractures05.00.70
1950a315-92b0-495c-b23e-461bb1148962.aspx
  
07.08.03iMedicalandSurgicalTreatmentofTemporomandibularJointDisorder07.08.03iMedicine (07)Medical and Surgical Treatment of Temporomandibular Joint Disorder1950a315-92b0-495c-b23e-461bb11489626067Medical and Surgical Treatment of Temporomandibular Joint Disorder07.08.03
bb08b5cc-c464-4f52-97b2-28a1416a6ba5.aspx
  
12.01.02bMedicalNecessity12.01.02bMiscellaneous (12)Medical Necessitybb08b5cc-c464-4f52-97b2-28a1416a6ba56503Medical Necessity12.01.02
add5dad9-edf0-49b1-8c22-d29d05068165.aspx
  
10.00.04MedicalNutritionTherapy(MNT)/NutritionCounseling10.00.04Rehabilitation Services (10)Medical Nutrition Therapy (MNT)/Nutrition Counselingadd5dad9-edf0-49b1-8c22-d29d050681656896Medical Nutrition Therapy (MNT)/Nutrition Counseling10.00.04
c1c3f72e-3e26-48d1-920e-6966db2d369a.aspx
  
11.14.03hMeniscalAllograftTransplantationandMeniscalImplants(IndependenceAdministrators)11.14.03hSurgery (11)Meniscal Allograft Transplantation and Meniscal Implants (Independence Administrators)c1c3f72e-3e26-48d1-920e-6966db2d369a6578Meniscal Allograft Transplantation and Meniscal Implants (Independence Administrators)11.14.03
{"6579": {"Id":6579,"MPAttachmentLetter":"A","Title":"ICD-10-CM codes","MPPolicyAttachmentInternalSourceId":8941,"PolicyAttachmentPageName":"45bb9eef-480c-4cb5-8094-6bc614753d72"},}
24207755-bd19-4fbf-8625-ff1efc4f6178.aspx
  
11.14.01hMentoplastyorGenioplasty11.14.01hSurgery (11)Mentoplasty or Genioplasty24207755-bd19-4fbf-8625-ff1efc4f61786506Mentoplasty or Genioplasty11.14.01
21874fac-26e1-4dad-b976-d7e95613351b.aspx
  
11.14.21kMicroprocessor-ControlledProsthesesforLower-ExtremityAmputees11.14.21kSurgery (11)Microprocessor-Controlled Prostheses for Lower-Extremity Amputees21874fac-26e1-4dad-b976-d7e95613351b6649Microprocessor-Controlled Prostheses for Lower-Extremity Amputees11.14.21
2bbd18b7-831e-4bf7-84c1-8f22c0d30d45.aspx
  
11.15.24aMigraineDeactivationSurgery11.15.24aSurgery (11)Migraine Deactivation Surgery2bbd18b7-831e-4bf7-84c1-8f22c0d30d456214Migraine Deactivation Surgery11.15.24
9bcbfef7-18de-42ef-87b6-55a80be01439.aspx
  
08.02.19Mirikizumab-mrkz(Omvoh™)forIntravenousUse08.02.19Pharmacy (08)Mirikizumab-mrkz (Omvoh™) for Intravenous Use9bcbfef7-18de-42ef-87b6-55a80be014396571Mirikizumab-mrkz (Omvoh™) for Intravenous Use08.02.19
72d46cbb-4484-45a9-b692-6a2f50ba4e59.aspx
  
08.02.01bMirvetuximabsoravtansine-gynx(Elahere™)08.02.01bPharmacy (08)Mirvetuximab soravtansine-gynx (Elahere™)72d46cbb-4484-45a9-b692-6a2f50ba4e596322Mirvetuximab soravtansine-gynx (Elahere™)08.02.01
de9e9c47-3bb4-480c-af79-6d57825dc617.aspx
  
03.00.15pModifier24:UnrelatedEvaluationandManagementServicebytheSamePhysicianorOtherQualifiedHealthCareProfessionalDuringaPostoperativePeriod03.00.15pClinical Logic (03)Modifier 24: Unrelated Evaluation and Management Service by the Same Physician or Other Qualified Health Care Professional During a Postoperative Periodde9e9c47-3bb4-480c-af79-6d57825dc6175064Modifier 24: Unrelated Evaluation and Management Service by the Same Physician or Other Qualified Health Care Professional During a Postoperative Period03.00.15
447c313a-5436-425f-b57c-46028e2d8c7a.aspx
  
03.00.06abModifier25:Significant,SeparatelyIdentifiableEvaluationandManagementServicebytheSamePhysicianorOtherQualifiedHealthCareProfessionalontheSameDayoftheProcedureorOtherService03.00.06abClinical Logic (03)Modifier 25: Significant, Separately Identifiable Evaluation and Management Service by the Same Physician or Other Qualified Health Care Professional on the Same Day of the Procedure or Other Service447c313a-5436-425f-b57c-46028e2d8c7a7090Modifier 25: Significant, Separately Identifiable Evaluation and Management Service by the Same Physician or Other Qualified Health Care Professional on the Same Day of the Procedure or Other Service03.00.06
{"7091": {"Id":7091,"MPAttachmentLetter":"B","Title":"Problem-focused E&M Codes appended with modifier 25 should be reimbursed at 50% of the applicable fee schedule amount when submitted on the same date of service by the same professional provider or other qualified health care provider, as a preventive E&","MPPolicyAttachmentInternalSourceId":9476,"PolicyAttachmentPageName":"91896999-c2c3-452f-875b-023c34502b90"},"7092": {"Id":7092,"MPAttachmentLetter":"A","Title":"E&M codes appended with modifier 25 should be reimbursed at 50% of the applicable fee schedule amount when submitted on the same date of service, by the same professional provider or other qualified health care provider, as a minor procedure.","MPPolicyAttachmentInternalSourceId":9477,"PolicyAttachmentPageName":"942a2919-0c99-4c05-9660-2c6219ccc48e"},}
fa6af219-5eba-4d42-863b-a2ff5d9ad211.aspx
  
03.00.05zModifier50:BilateralProcedure03.00.05zClinical Logic (03)Modifier 50: Bilateral Procedurefa6af219-5eba-4d42-863b-a2ff5d9ad2116915Modifier 50: Bilateral Procedure03.00.05
c089bb2c-423f-4e85-8d78-7e2522acf4bf.aspx
  
03.00.32bModifier52:ReducedServices03.00.32bClinical Logic (03)Modifier 52: Reduced Servicesc089bb2c-423f-4e85-8d78-7e2522acf4bf5522Modifier 52: Reduced Services03.00.32
b835e172-8f47-42be-a0cf-3f63a7d3133d.aspx
  
03.00.33bModifier53:DiscontinuedProcedure03.00.33bClinical Logic (03)Modifier 53: Discontinued Procedureb835e172-8f47-42be-a0cf-3f63a7d3133d5523Modifier 53: Discontinued Procedure03.00.33
b5c59444-0f62-4fcb-8717-62bb24a5bbaf.aspx
  
03.00.16pModifier57:DecisionforSurgery03.00.16pClinical Logic (03)Modifier 57: Decision for Surgeryb5c59444-0f62-4fcb-8717-62bb24a5bbaf5489Modifier 57:  Decision for Surgery03.00.16
122b6437-68a7-47a3-ad58-b8d7b6959500.aspx
  
00.10.11abModifier62:TwoSurgeons00.10.11abAdministrative (00)Modifier 62: Two Surgeons122b6437-68a7-47a3-ad58-b8d7b69595006916Modifier 62: Two Surgeons00.10.11
cee9d4a3-ebc8-4a88-b14f-de037afbcbe6.aspx
  
00.10.17oModifier66:SurgicalTeam00.10.17oAdministrative (00)Modifier 66: Surgical Teamcee9d4a3-ebc8-4a88-b14f-de037afbcbe65980Modifier 66: Surgical Team00.10.17
{"5981": {"Id":5981,"MPAttachmentLetter":"A","Title":"Team Surgery Review Form","MPPolicyAttachmentInternalSourceId":8358,"PolicyAttachmentPageName":"24fdde6f-63ee-472b-9e9e-00fd65735f42"},}
42176633-901e-445a-8b52-c1d8653c85bf.aspx
  
03.00.02cModifier76:RepeatProcedureorServicebySamePhysicianorOtherQualifiedHealthCareProfessional03.00.02cClinical Logic (03)Modifier 76: Repeat Procedure or Service by Same Physician or Other Qualified Health Care Professional42176633-901e-445a-8b52-c1d8653c85bf5104Modifier 76: Repeat Procedure or Service by Same Physician or Other Qualified Health Care Professional03.00.02
37236b28-776f-4b06-9c4f-02834e055984.aspx
  
03.00.11cModifier77:RepeatProcedureorServicebyAnotherPhysicianorOtherQualifiedHealthCareProfessional03.00.11cClinical Logic (03)Modifier 77: Repeat Procedure or Service by Another Physician or Other Qualified Health Care Professional37236b28-776f-4b06-9c4f-02834e0559845101Modifier 77: Repeat Procedure or Service by Another Physician or Other Qualified Health Care Professional03.00.11
e6f338ca-9339-4559-a434-d115fab590e0.aspx
  
03.00.12gModifier78:UnplannedReturntotheOperating/ProcedureRoombytheSamePhysicianorOtherQualifiedHealthCareProfessionalFollowingtheInitialProcedureforaRelatedProcedureDuringthePostoperativePeriod03.00.12gClinical Logic (03)Modifier 78: Unplanned Return to the Operating/Procedure Room by the Same Physician or Other Qualified Health Care Professional Following the Initial Procedure for a Related Procedure During the Postoperative Periode6f338ca-9339-4559-a434-d115fab590e05105Modifier 78: Unplanned Return to the Operating/Procedure Room by the Same Physician or Other Qualified Health Care Professional Following the Initial Procedure for a Related Procedure During the Postoperative Period03.00.12
eda29625-d354-43e3-a2cf-888ee03cc897.aspx
  
03.00.28nModifier79:UnrelatedProcedureorServicebytheSamePhysicianorOtherQualifiedHealthCareProfessionalDuringthePostoperativePeriod03.00.28nClinical Logic (03)Modifier 79: Unrelated Procedure or Service by the Same Physician or Other Qualified Health Care Professional During the Postoperative Periodeda29625-d354-43e3-a2cf-888ee03cc8975102Modifier 79:  Unrelated Procedure or Service by the Same Physician or Other Qualified Health Care Professional During the Postoperative Period03.00.28
42f028a1-e4b4-4c50-82cb-05fc6c8314d0.aspx
  
03.00.20tModifiers26(ProfessionalComponent)andTC(TechnicalComponent)03.00.20tClinical Logic (03)Modifiers 26 (Professional Component) and TC (Technical Component)42f028a1-e4b4-4c50-82cb-05fc6c8314d07089Modifiers 26 (Professional Component) and TC (Technical Component)03.00.20
6f51046e-5480-4081-8e50-e246466d3c73.aspx
  
00.10.18yModifiersforAssistant-at-SurgeryServices:80,81,82,andAS00.10.18yAdministrative (00)Modifiers for Assistant-at-Surgery Services: 80, 81, 82, and AS6f51046e-5480-4081-8e50-e246466d3c736746Modifiers for Assistant-at-Surgery Services: 80, 81, 82, and AS00.10.18
0e19258a-b273-40cc-97ad-49f9bf2c9f4c.aspx
  
03.00.31gModifiersforSplitorSharedSurgicalServices(Modifiers54,55,and56)03.00.31gClinical Logic (03)Modifiers for Split or Shared Surgical Services (Modifiers 54, 55, and 56)0e19258a-b273-40cc-97ad-49f9bf2c9f4c5520Modifiers for Split or Shared Surgical Services (Modifiers 54, 55, and 56)03.00.31
eba0dc49-63b2-4445-9acc-208c2f6b979e.aspx
  
03.00.08fModifiersXE,XS,XP,XU,and5903.00.08fClinical Logic (03)Modifiers XE, XS, XP, XU, and 59eba0dc49-63b2-4445-9acc-208c2f6b979e6631Modifiers XE, XS, XP, XU, and 5903.00.08
60ea10d4-db3c-4d7c-a253-20b66ed4e7e2.aspx
  
08.01.52fMogamulizumab-kpkc(Poteligeo®)08.01.52fPharmacy (08)Mogamulizumab-kpkc (Poteligeo®)60ea10d4-db3c-4d7c-a253-20b66ed4e7e26323Mogamulizumab-kpkc (Poteligeo®)08.01.52
d2afa137-cc2f-4a14-8d24-28c4eda18252.aspx
  
11.08.23kMohsMicrographicSurgery11.08.23kSurgery (11)Mohs Micrographic Surgeryd2afa137-cc2f-4a14-8d24-28c4eda182526090Mohs Micrographic Surgery11.08.23
{"6091": {"Id":6091,"MPAttachmentLetter":"A","Title":"ICD 10 Codes","MPPolicyAttachmentInternalSourceId":8479,"PolicyAttachmentPageName":"bd0ed2ed-dab4-4dce-bab8-93180a43ff67"},}
e0a90c62-6b50-403d-bdfe-f6b6ea545afd.aspx
  
06.02.36dMolecularTestingfortheManagementofPancreaticCystsorBarrett'sEsophagus(IndependenceAdministrators)06.02.36dPathology and Laboratory (06)Molecular Testing for the Management of Pancreatic Cysts or Barrett's Esophagus (Independence Administrators)e0a90c62-6b50-403d-bdfe-f6b6ea545afd5283Molecular Testing for the Management of Pancreatic Cysts or Barrett's Esophagus (Independence Administrators)06.02.36
95fb0852-74d3-4b07-8760-d77ab5981fd3.aspx
  
08.01.93eMonoclonalAntibodiesDirectedAgainstAmyloidfortheTreatmentofAlzheimerDisease08.01.93ePharmacy (08)Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer Disease95fb0852-74d3-4b07-8760-d77ab5981fd36900Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer Disease08.01.93
72ac7bea-3bbc-4a29-9d19-7f8e45327c67.aspx
  
08.02.00bMosunetuzumab-axgb(Lunsumio™)08.02.00bPharmacy (08)Mosunetuzumab-axgb (Lunsumio™)72ac7bea-3bbc-4a29-9d19-7f8e45327c676163Mosunetuzumab-axgb (Lunsumio™)08.02.00
4fc4b535-f234-481b-96c2-e7e84fcaecd4.aspx
  
06.02.32dMultigeneExpressionAssaysforPredictingRecurrenceinColonCancer(IndependenceAdministrators)06.02.32dPathology and Laboratory (06)Multigene Expression Assays for Predicting Recurrence in Colon Cancer (Independence Administrators)4fc4b535-f234-481b-96c2-e7e84fcaecd46211Multigene Expression Assays for Predicting Recurrence in Colon Cancer (Independence Administrators)06.02.32
1decf4ce-ff05-4578-b4ab-1846c812b195.aspx
  
00.01.60iMultipleProcedurePaymentReduction(MPPR)onCertainDiagnosticServices00.01.60iAdministrative (00)Multiple Procedure Payment Reduction (MPPR) on Certain Diagnostic Services1decf4ce-ff05-4578-b4ab-1846c812b1955875Multiple Procedure Payment Reduction (MPPR) on Certain Diagnostic Services00.01.60
{}
4d788700-fa17-4cdd-840b-edd1ae23c9de.aspx
  
00.01.68bMultipleProcedurePaymentReductionGuidelinesforPhysical,Occupational,andSpeechTherapyServices00.01.68bAdministrative (00)Multiple Procedure Payment Reduction Guidelines for Physical, Occupational, and Speech Therapy Services4d788700-fa17-4cdd-840b-edd1ae23c9de6368Multiple Procedure Payment Reduction Guidelines for Physical, Occupational, and Speech Therapy Services00.01.68
{"6369": {"Id":6369,"MPAttachmentLetter":"A","Title":"Multiple Reduction Always Therapy Procedure Codes","MPPolicyAttachmentInternalSourceId":8720,"PolicyAttachmentPageName":"fe2a6487-915a-4e8f-a3f0-78d28254ed21"},}
10b463d3-2bb6-459b-8b1d-f17a56eb5f88.aspx
  
11.00.10yMultipleSurgeryPaymentReduction11.00.10ySurgery (11)Multiple Surgery Payment Reduction10b463d3-2bb6-459b-8b1d-f17a56eb5f886954Multiple Surgery Payment Reduction11.00.10
{}
8a04f83e-796b-4281-a6e7-752b33f63ac7.aspx
  
00.01.66oMusculoskeletalServices(Independence)00.01.66oAdministrative (00)Musculoskeletal Services (Independence)8a04f83e-796b-4281-a6e7-752b33f63ac76984Musculoskeletal Services (Independence)00.01.66
{"6985": {"Id":6985,"MPAttachmentLetter":"C","Title":"Procedures Codes for Interventional Pain Management","MPPolicyAttachmentInternalSourceId":9373,"PolicyAttachmentPageName":"7378fe98-39b3-48b7-9aa0-42ffd318e32e"},"6986": {"Id":6986,"MPAttachmentLetter":"B","Title":"Procedure Codes for Joint Surgery","MPPolicyAttachmentInternalSourceId":9374,"PolicyAttachmentPageName":"201d3b20-1d7c-4b0a-b3b8-e2577e016351"},"6987": {"Id":6987,"MPAttachmentLetter":"A","Title":"Procedure Codes for Spinal Surgery","MPPolicyAttachmentInternalSourceId":9375,"PolicyAttachmentPageName":"26fc3b7b-e66b-4280-aa43-80fbd794807f"},}
28d9baa9-72c2-4bf9-a06b-c6a66e7a6e6e.aspx
  
08.02.11bNadofarageneFiradenovec-vncg(Adstiladrin®)08.02.11bPharmacy (08)Nadofaragene Firadenovec-vncg (Adstiladrin®)28d9baa9-72c2-4bf9-a06b-c6a66e7a6e6e6817Nadofaragene Firadenovec-vncg (Adstiladrin®)08.02.11
5a9f46b9-076b-432e-911f-6f988f7eb7e0.aspx
  
08.00.64hNatalizumab(Tysabri®)andRelatedBiosimilars08.00.64hPharmacy (08)Natalizumab (Tysabri®) and Related Biosimilars5a9f46b9-076b-432e-911f-6f988f7eb7e06136Natalizumab (Tysabri®) and Related Biosimilars08.00.64
f9a23570-9bcf-4c3d-b80c-800b09727c20.aspx
  
00.01.56bNationalCorrectCodingInitiative(NCCI)CodePairEdits00.01.56bAdministrative (00)National Correct Coding Initiative (NCCI) Code Pair Editsf9a23570-9bcf-4c3d-b80c-800b09727c205521National Correct Coding Initiative (NCCI) Code Pair Edits00.01.56
c854ca91-0ae0-42e0-b507-b928491d10e7.aspx
  
05.00.15tNebulizersandInhalationSolutions05.00.15tDME (05)Nebulizers and Inhalation Solutionsc854ca91-0ae0-42e0-b507-b928491d10e76832Nebulizers and Inhalation Solutions05.00.15
49d423dc-c100-4119-96c9-325d9c3971db.aspx
  
05.00.38mNegativePressureWoundTherapySystems05.00.38mDME (05)Negative Pressure Wound Therapy Systems49d423dc-c100-4119-96c9-325d9c3971db5779Negative Pressure Wound Therapy Systems05.00.38
b666bcb7-bdc6-4813-9738-a428187bfc09.aspx
  
06.02.38dNerveFiberDensityTesting06.02.38dPathology and Laboratory (06)Nerve Fiber Density Testingb666bcb7-bdc6-4813-9738-a428187bfc096498Nerve Fiber Density Testing06.02.38
920611f4-d021-4c4f-8b7a-db41eaa19492.aspx
  
05.00.73gNeuromuscularElectricalStimulators(NMES)andFunctionalElectricalStimulators(FES)05.00.73gDME (05)Neuromuscular Electrical Stimulators (NMES) and Functional Electrical Stimulators (FES)920611f4-d021-4c4f-8b7a-db41eaa194926329Neuromuscular Electrical Stimulators (NMES) and Functional Electrical Stimulators (FES)05.00.73
5d8e82ee-3645-4d22-8341-e7c4aef3a697.aspx
  
07.03.08oNeuropsychologicalTestingforNeurologicallyBasedConditions07.03.08oMedicine (07)Neuropsychological Testing for Neurologically Based Conditions5d8e82ee-3645-4d22-8341-e7c4aef3a6976912Neuropsychological Testing for Neurologically Based Conditions07.03.08
{"6913": {"Id":6913,"MPAttachmentLetter":"A","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":8990,"PolicyAttachmentPageName":"5a3b9f1d-5e1b-4e73-859a-f7d2bb9636d1"},}
335dc023-63c8-481b-bd7c-7e95bce642c2.aspx
  
00.01.44jNeverEventsandPreventableSeriousAdverseEvents00.01.44jAdministrative (00)Never Events and Preventable Serious Adverse Events335dc023-63c8-481b-bd7c-7e95bce642c26400Never Events and Preventable Serious Adverse Events00.01.44
{"6401": {"Id":6401,"MPAttachmentLetter":"C","Title":"Never Event or Preventable Serious Adverse Event Reporting Form","MPPolicyAttachmentInternalSourceId":8813,"PolicyAttachmentPageName":"86c56a21-135b-415f-af11-e8c09fb82599"},"6402": {"Id":6402,"MPAttachmentLetter":"A","Title":"Pennsylvania House Bill No. 84 addressing Never Events and Preventable Serious Adverse Events","MPPolicyAttachmentInternalSourceId":8814,"PolicyAttachmentPageName":"3489e612-c454-4775-8c33-15bbbf69f7f6"},"6403": {"Id":6403,"MPAttachmentLetter":"B","Title":"New Jersey Act No. 2471","MPPolicyAttachmentInternalSourceId":8815,"PolicyAttachmentPageName":"add9372b-2bdd-482b-b1d4-8b92fa7e94d8"},}
51aa044f-26fa-4604-9128-64d319b95cca.aspx
  
08.01.62dNivolumab(Opdivo®)08.01.62dPharmacy (08)Nivolumab (Opdivo®)51aa044f-26fa-4604-9128-64d319b95cca6680Nivolumab (Opdivo®)08.01.62
{"6681": {"Id":6681,"MPAttachmentLetter":"A","Title":"ICD-10 Codes and Narratives","MPPolicyAttachmentInternalSourceId":9101,"PolicyAttachmentPageName":"aba99468-c529-4155-a79a-e64566d4e69a"},}
a94a1888-1f39-468f-9f06-abf9336d3587.aspx
  
08.01.94cNivolumabandRelatlimab-rmbw(Opdualag™)08.01.94cPharmacy (08)Nivolumab and Relatlimab-rmbw (Opdualag™) a94a1888-1f39-468f-9f06-abf9336d35876169Nivolumab and Relatlimab-rmbw (Opdualag™) 08.01.94
13b9c97f-ff4d-43d9-b34a-c0f632675400.aspx
  
07.10.05nNoncontraceptiveUseoftheLevonorgestrel-ReleasingIntrauterineSystem07.10.05nMedicine (07)Noncontraceptive Use of the Levonorgestrel-Releasing Intrauterine System13b9c97f-ff4d-43d9-b34a-c0f6326754006423Noncontraceptive Use of the Levonorgestrel-Releasing Intrauterine System07.10.05
baa4ece9-98ba-4323-a3b4-ceeff01fedb4.aspx
  
07.03.25aNonemergentInpatientVideoElectroencephalogram(EEG)MonitoringandAmbulatoryEEGMonitoringintheHome07.03.25aMedicine (07)Nonemergent Inpatient Video Electroencephalogram (EEG) Monitoring and Ambulatory EEG Monitoring in the Homebaa4ece9-98ba-4323-a3b4-ceeff01fedb46502Nonemergent Inpatient Video Electroencephalogram (EEG) Monitoring and Ambulatory EEG Monitoring in the Home07.03.25
57540b80-7f18-4548-98c7-4638cdca52bc.aspx
  
06.02.47fNoninvasivePrenatalScreeningforFetalAneuploidiesUsingCell-FreeFetalDNA(IndependenceAdministrators)06.02.47fPathology and Laboratory (06)Noninvasive Prenatal Screening for Fetal Aneuploidies Using Cell-Free Fetal DNA (Independence Administrators)57540b80-7f18-4548-98c7-4638cdca52bc7084Noninvasive Prenatal Screening for Fetal Aneuploidies Using Cell-Free Fetal DNA (Independence Administrators)06.02.47
295f32d5-9491-4fc9-adff-c1e4573a8a21.aspx
  
05.00.30pNoninvasiveRespiratoryAssistDevices(RADs):ContinuousPositiveAirwayPressure(CPAP)Devices,Auto-AdjustingPositiveAirwayPressure(APAP)andBi-LevelDevices05.00.30pDME (05)Noninvasive Respiratory Assist Devices (RADs): Continuous Positive Airway Pressure (CPAP) Devices, Auto-Adjusting Positive Airway Pressure (APAP) and Bi-Level Devices295f32d5-9491-4fc9-adff-c1e4573a8a216573Noninvasive Respiratory Assist Devices (RADs): Continuous Positive Airway Pressure (CPAP) Devices, Auto-Adjusting Positive Airway Pressure (APAP) and Bi-Level Devices05.00.30
9c7a1087-5c3f-4665-b4a9-c12cd594006d.aspx
  
06.02.56iNoninvasiveTechniquesfortheEvaluationandMonitoringofIndividualswithChronicLiverDisease06.02.56iPathology and Laboratory (06)Noninvasive Techniques for the Evaluation and Monitoring of Individuals with Chronic Liver Disease9c7a1087-5c3f-4665-b4a9-c12cd594006d7053Noninvasive Techniques for the Evaluation and Monitoring of Individuals with Chronic Liver Disease06.02.56
b02f004a-3f5f-49af-aff7-4c1f6299e9f1.aspx
  
07.08.01fNon-SurgicalSpinalDecompressionTherapy07.08.01fMedicine (07)Non-Surgical Spinal Decompression Therapyb02f004a-3f5f-49af-aff7-4c1f6299e9f16076Non-Surgical Spinal Decompression Therapy07.08.01
43dd1977-9420-4cbb-a74d-ac0a2d28adee.aspx
  
00.01.24kNotMedicallyNecessaryServicesandObsoleteorUnreliableDiagnosticTests00.01.24kAdministrative (00)Not Medically Necessary Services and Obsolete or Unreliable Diagnostic Tests43dd1977-9420-4cbb-a74d-ac0a2d28adee6364Not Medically Necessary Services and Obsolete or Unreliable Diagnostic Tests00.01.24
58ba51cb-1c54-4697-8bb4-1ecbbd406190.aspx
  
11.15.19eNucleoplasty11.15.19eSurgery (11)Nucleoplasty58ba51cb-1c54-4697-8bb4-1ecbbd4061906326Nucleoplasty11.15.19
435660d4-7c54-452f-bcc7-4a76f0c9ef7a.aspx
  
08.00.18qNutritionalFormulas,EnteralNutrition,MedicalFoods,Low-ProteinModifiedFoodProducts,andDonatedBreastMilk08.00.18qPharmacy (08)Nutritional Formulas, Enteral Nutrition, Medical Foods, Low-Protein Modified Food Products, and Donated Breast Milk435660d4-7c54-452f-bcc7-4a76f0c9ef7a6610Nutritional Formulas, Enteral Nutrition, Medical Foods, Low-Protein Modified Food Products, and Donated Breast Milk08.00.18
{"6611": {"Id":6611,"MPAttachmentLetter":"C","Title":"Caloric Requirements","MPPolicyAttachmentInternalSourceId":8363,"PolicyAttachmentPageName":"42e3e8cf-53a8-4998-b2c0-0a647c5e2eda"},"6612": {"Id":6612,"MPAttachmentLetter":"A","Title":"PA Mandates","MPPolicyAttachmentInternalSourceId":8663,"PolicyAttachmentPageName":"bfb4fd8f-93c5-4d1d-b2dc-434af48c0a30"},"6613": {"Id":6613,"MPAttachmentLetter":"B","Title":"NJ Mandates","MPPolicyAttachmentInternalSourceId":8664,"PolicyAttachmentPageName":"98e001d1-bc6d-4fb7-96cb-e9cef6e17eb8"},}
7f8302c2-19f4-4ddb-8f99-4a0bfa735caf.aspx
  
00.03.10FObstetricalUltrasoundsforMembersEnrolledinaHealthMaintenanceOrganization(HMO)orHealthMaintenanceOrganizationPoint-of-Service(HMO-POS)Product00.03.10FAdministrative (00)Obstetrical Ultrasounds for Members Enrolled in a Health Maintenance Organization (HMO) or Health Maintenance Organization Point-of-Service (HMO-POS) Product7f8302c2-19f4-4ddb-8f99-4a0bfa735caf5560Obstetrical Ultrasounds for Members Enrolled in a Health Maintenance Organization (HMO) or Health Maintenance Organization Point-of-Service (HMO-POS) Product00.03.10
{"5561": {"Id":5561,"MPAttachmentLetter":"B","Title":"Rule out Ectopic Pregnancy","MPPolicyAttachmentInternalSourceId":7548,"PolicyAttachmentPageName":"93506959-7870-42f1-aab0-85b9aa8f67dd"},"5562": {"Id":5562,"MPAttachmentLetter":"C","Title":"Rule out intrauterine pathology and Screening for Fetal abnormalities","MPPolicyAttachmentInternalSourceId":7549,"PolicyAttachmentPageName":"b1e7dbb7-62be-499f-a75c-1852e92dae11"},"5563": {"Id":5563,"MPAttachmentLetter":"A","Title":"High Risk Pregnancy","MPPolicyAttachmentInternalSourceId":7550,"PolicyAttachmentPageName":"79c5e79c-da07-4d3f-a0c8-3cdef56fd0dd"},"5564": {"Id":5564,"MPAttachmentLetter":"D","Title":"First-trimester screening and Ovarian Dysfunction","MPPolicyAttachmentInternalSourceId":7551,"PolicyAttachmentPageName":"e83b73f7-1ee4-4c48-a27a-5307de6ba5af"},}
a46722d8-70d8-4f2b-8a3a-3a05bf1e9e47.aspx
  
08.01.38cOcrelizumab(Ocrevus®)08.01.38cPharmacy (08)Ocrelizumab (Ocrevus®)a46722d8-70d8-4f2b-8a3a-3a05bf1e9e476204Ocrelizumab (Ocrevus®)08.01.38
5d1e5573-c880-46bf-abfc-d4fb8503c388.aspx
  
08.01.10jOctreotideAcetate(Sandostatin®LARDepot)08.01.10jPharmacy (08)Octreotide Acetate (Sandostatin® LAR Depot)5d1e5573-c880-46bf-abfc-d4fb8503c3886694Octreotide Acetate (Sandostatin® LAR Depot)08.01.10
{"6695": {"Id":6695,"MPAttachmentLetter":"A","Title":"ICD-10 CODES AND NARRATIVES","MPPolicyAttachmentInternalSourceId":9105,"PolicyAttachmentPageName":"80f8194e-57a5-4187-9fc8-4b6e56fd7ac5"},}
c71c0b6a-978f-48b5-a9ef-21f4bc410161.aspx
  
08.00.15fOff-labelCoverageforPrescriptionDrugsand/orBiologics08.00.15fPharmacy (08)Off-label Coverage for Prescription Drugs and/or Biologicsc71c0b6a-978f-48b5-a9ef-21f4bc4101616626Off-label Coverage for Prescription Drugs and/or Biologics08.00.15
82766385-cc7c-4d38-92a3-60d3a64891cc.aspx
  
08.01.96aolipudasealfa-rpcp(Xenpozyme™)08.01.96aPharmacy (08)olipudase alfa-rpcp (Xenpozyme™)82766385-cc7c-4d38-92a3-60d3a64891cc6020olipudase alfa-rpcp (Xenpozyme™)08.01.96
{"6021": {"Id":6021,"MPAttachmentLetter":"A","Title":"Dosing and Frequency Requirements for olipudase alfa-rpcp (Xenpozyme)","MPPolicyAttachmentInternalSourceId":8307,"PolicyAttachmentPageName":"0625ef2b-5709-4de4-b2c2-29b854d42dfd"},}
a012a52c-6653-4582-b0d3-a26ca273326b.aspx
  
08.00.55lOmalizumab(Xolair®)08.00.55lPharmacy (08)Omalizumab (Xolair®)a012a52c-6653-4582-b0d3-a26ca273326b7022Omalizumab (Xolair®)08.00.55
{"7023": {"Id":7023,"MPAttachmentLetter":"A","Title":"Dosing and Frequency Requirements for Omalizumab (Xolair®)","MPPolicyAttachmentInternalSourceId":9229,"PolicyAttachmentPageName":"7a9afb97-0bb2-4b83-879c-d0607db229d0"},}
6805c0ac-0631-4eb5-9b58-51b0b72e4c6a.aspx
  
11.14.08dOrthognathicSurgery11.14.08dSurgery (11)Orthognathic Surgery6805c0ac-0631-4eb5-9b58-51b0b72e4c6a6055Orthognathic Surgery11.14.08
4af2009d-12eb-47ca-8a30-d4feb336ceb5.aspx
  
07.13.01kOrthoptic/PleopticTraining07.13.01kMedicine (07)Orthoptic/Pleoptic Training4af2009d-12eb-47ca-8a30-d4feb336ceb56520Orthoptic/Pleoptic Training07.13.01
c5bbc564-020e-4118-be30-6a64af0719ea.aspx
  
11.14.12fOsteochondralAllograftTransplantation(IndependenceAdministrators)11.14.12fSurgery (11)Osteochondral Allograft Transplantation (Independence Administrators)c5bbc564-020e-4118-be30-6a64af0719ea6601Osteochondral Allograft Transplantation (Independence Administrators)11.14.12
dc351354-56b1-420b-a53f-9e139e0b31a9.aspx
  
11.14.09hOsteochondralAutograftTransplantation(IndependenceAdministrators)11.14.09hSurgery (11)Osteochondral Autograft Transplantation (Independence Administrators)dc351354-56b1-420b-a53f-9e139e0b31a96602Osteochondral Autograft Transplantation (Independence Administrators)11.14.09
67833537-3aa0-4e81-a63d-cf64be38d5b2.aspx
  
05.00.81aOsteogenicStimulators(non-invasive,invasive/semi-invasive,electricalandultrasound)05.00.81aDME (05)Osteogenic Stimulators (non-invasive, invasive/semi-invasive, electrical and ultrasound)67833537-3aa0-4e81-a63d-cf64be38d5b26580Osteogenic Stimulators (non-invasive, invasive/semi-invasive, electrical and ultrasound)05.00.81
9e31cf31-d670-4f98-91af-d3ec7a9e93ef.aspx
  
05.00.50oOstomySupplies05.00.50oDME (05)Ostomy Supplies9e31cf31-d670-4f98-91af-d3ec7a9e93ef6507Ostomy Supplies05.00.50
{"6508": {"Id":6508,"MPAttachmentLetter":"A","Title":"HCPCS Codes for Ostomy Supplies","MPPolicyAttachmentInternalSourceId":8868,"PolicyAttachmentPageName":"a38a85e0-a16b-44dc-a8ed-c49209411833"},}
58df21df-3284-4798-9731-6f9040b9d45a.aspx
  
11.01.01jOtoplastyorNon-SurgicalExternalEarMolding11.01.01jSurgery (11)Otoplasty or Non-Surgical External Ear Molding58df21df-3284-4798-9731-6f9040b9d45a6645Otoplasty or Non-Surgical External Ear Molding11.01.01
14e4a1df-d766-40d5-b280-eace3f7f69d1.aspx
  
12.05.01jOutpatientDiabetesEducationandSelf-ManagementTraining12.05.01jMiscellaneous (12)Outpatient Diabetes Education and Self-Management Training14e4a1df-d766-40d5-b280-eace3f7f69d12625Outpatient Diabetes Education and Self-Management Training12.05.01
{"2626": {"Id":2626,"MPAttachmentLetter":"A","Title":"ICD-10 CM Codes Eligible to be Reported for Outpatient Diabetes Education and Self-Management Training (E08.00- E10.3491)","MPPolicyAttachmentInternalSourceId":2371,"PolicyAttachmentPageName":"ed035dfc-85f7-4a19-b93a-5a68d1226e03"},"2627": {"Id":2627,"MPAttachmentLetter":"B","Title":"ICD-10 CM Codes Eligible to be Reported for Outpatient Diabetes Education and Self-Management Training (E10.3492- E13.37X2), Continued","MPPolicyAttachmentInternalSourceId":2372,"PolicyAttachmentPageName":"bd6c3245-6e36-47c4-b728-9b5efac2262f"},"2628": {"Id":2628,"MPAttachmentLetter":"C","Title":"ICD-10 CM Codes Eligible to be Reported for Outpatient Diabetes Education and Self-Management Training (E13.37X3- P70.2), Continued","MPPolicyAttachmentInternalSourceId":2373,"PolicyAttachmentPageName":"a903e29d-10c8-4b14-a150-f61bffb56003"},}
5cb7351b-c0f6-4bf6-a9a8-3109571bd6fb.aspx
  
10.03.01oOutpatientPhysicalMedicine,Rehabilitation,andHabilitationServices10.03.01oRehabilitation Services (10)Outpatient Physical Medicine, Rehabilitation, and Habilitation Services5cb7351b-c0f6-4bf6-a9a8-3109571bd6fb6012Outpatient Physical Medicine, Rehabilitation, and Habilitation Services10.03.01
723a7d76-536e-4781-b75b-5d23704d4fb7.aspx
  
00.03.03iOutpatientShort-TermRehabilitationServicesIncludedinCapitation00.03.03iAdministrative (00)Outpatient Short-Term Rehabilitation Services Included in Capitation723a7d76-536e-4781-b75b-5d23704d4fb75576Outpatient Short-Term Rehabilitation Services Included in Capitation00.03.03
{"5577": {"Id":5577,"MPAttachmentLetter":"A","Title":"No Title","MPPolicyAttachmentInternalSourceId":7603,"PolicyAttachmentPageName":"e3568853-d080-4f2e-ad60-2cc28a1b9be4"},}
83fb20db-ff19-4f94-960f-986ee8ee0d15.aspx
  
11.06.07eOvarianandInternalIliacVeinEmbolizationasTreatmentforPelvicCongestionSyndrome11.06.07eSurgery (11)Ovarian and Internal Iliac Vein Embolization as Treatment for Pelvic Congestion Syndrome83fb20db-ff19-4f94-960f-986ee8ee0d157007Ovarian and Internal Iliac Vein Embolization as Treatment for Pelvic Congestion Syndrome11.06.07
fb1e4d68-a024-4e07-8042-d06655d3d86e.aspx
  
08.00.90sPaclitaxelProtein-BoundParticlesforInjectableSuspension(Albumin-Bound)/(Abraxane®forInjectableSuspension)08.00.90sPharmacy (08)Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound)/(Abraxane® for Injectable Suspension)fb1e4d68-a024-4e07-8042-d06655d3d86e6977Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound)/(Abraxane® for Injectable Suspension)08.00.90
{"6978": {"Id":6978,"MPAttachmentLetter":"A","Title":"ICD-10 codes","MPPolicyAttachmentInternalSourceId":9352,"PolicyAttachmentPageName":"51250650-1f9a-4967-aede-011d8075670a"},}
a69f8000-b53d-462b-a2c8-2e5dc19e19f6.aspx
  
07.03.27PainManagementofPeripheralNervesbyInjection07.03.27Medicine (07)Pain Management of Peripheral Nerves by Injectiona69f8000-b53d-462b-a2c8-2e5dc19e19f66841Pain Management of Peripheral Nerves by Injection07.03.27
fc96e0df-db10-4272-b4ef-87b0ab7506b5.aspx
  
08.00.22qPalivizumab(Synagis)08.00.22qPharmacy (08)Palivizumab (Synagis)fc96e0df-db10-4272-b4ef-87b0ab7506b56577Palivizumab (Synagis)08.00.22
fd68f44f-7448-46e7-9cfc-f3f862c64c3a.aspx
  
11.08.06kPanniculectomy,Abdominoplasty,AbdominalLipectomy,andOtherExcisionsofRedundantSkin11.08.06kSurgery (11)Panniculectomy, Abdominoplasty, Abdominal Lipectomy, and Other Excisions of Redundant Skinfd68f44f-7448-46e7-9cfc-f3f862c64c3a6685Panniculectomy, Abdominoplasty, Abdominal Lipectomy, and Other Excisions of Redundant Skin11.08.06
{"6686": {"Id":6686,"MPAttachmentLetter":"A","Title":"ICD-10 codes","MPPolicyAttachmentInternalSourceId":9107,"PolicyAttachmentPageName":"96c69835-3b7e-4b55-911d-bbd22489953c"},}
Previous201 - 300Next